Physician profile
Hai P Bui
NPI 1316965536
$7,727.15
in general payments reported to CMS, 2019-2025
32 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $711 · 2021: $1,272 · 2022: $1,173 · 2023: $1,314 · 2024: $774 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782 · Education: $45.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.72 |
| Education | $45.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,841.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $947.10 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $670.01 | 2019-2023 | Xarelto |
| Abbvie INC. | $654.21 | 2019-2025 | Vraylar |
| Biohaven Pharmaceuticals, INC. | $343.01 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.38 | 2022-2024 | |
| Pfizer INC. | $304.73 | 2019-2025 | |
| Lilly USA, LLC | $261.40 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $259.99 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $166.31 | 2019-2021 | |
| Gilead Sciences, INC. | $132.83 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $116.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $92.49 | 2021 | |
| Novo Nordisk INC | $81.48 | 2020-2024 | Rybelsus, Ozempic |
| Nestle Healthcare Nutrition INC. | $70.77 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $62.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.92 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $50.41 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $41.45 | 2023-2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $35.17 | 2019 | |
| Hikma Pharmaceuticals USA | $34.66 | 2019 | |
| Seqirus USA INC | $21.87 | 2024 | Flucelvax, Fluad |
| Smith+Nephew, INC. | $20.57 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $20.00 | 2022 | |
| Medtronic, INC. | $19.69 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.12 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.95 | 2019 | |
| Daiichi Sankyo INC. | $18.93 | 2021 | |
| Sumitomo Pharma America, INC. | $18.41 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $16.54 | 2022 | |
| Avion Pharmaceuticals | $12.38 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hai Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.